REPORT FROM THE ACTRIMS-ECTRIMS – BOSTON, MA, SEPTEMBER 10-13, 2014 – The proliferation of new treatments in development for MS has made it increasingly challenging to recruit a sufficient number of eligible study subjects, most notably for studies involving pediatric or untreated patients.